211 related articles for article (PubMed ID: 37069690)
41. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.
Sartore-Bianchi A; Gasparri F; Galvani A; Nici L; Darnowski JW; Barbone D; Fennell DA; Gaudino G; Porta C; Mutti L
Clin Cancer Res; 2007 Oct; 13(19):5942-51. PubMed ID: 17908991
[TBL] [Abstract][Full Text] [Related]
42. Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition.
Mimura N; Hideshima T; Shimomura T; Suzuki R; Ohguchi H; Rizq O; Kikuchi S; Yoshida Y; Cottini F; Jakubikova J; Cirstea D; Gorgun G; Minami J; Tai YT; Richardson PG; Utsugi T; Iwama A; Anderson KC
Cancer Res; 2014 Aug; 74(16):4458-69. PubMed ID: 24934808
[TBL] [Abstract][Full Text] [Related]
43. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
[TBL] [Abstract][Full Text] [Related]
44. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
Gordon GJ; Mani M; Maulik G; Mukhopadhyay L; Yeap BY; Kindler HL; Salgia R; Sugarbaker DJ; Bueno R
Cancer Chemother Pharmacol; 2008 Apr; 61(4):549-58. PubMed ID: 17522864
[TBL] [Abstract][Full Text] [Related]
45. Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells.
Rao R; Nalluri S; Fiskus W; Savoie A; Buckley KM; Ha K; Balusu R; Joshi A; Coothankandaswamy V; Tao J; Sotomayor E; Atadja P; Bhalla KN
Clin Cancer Res; 2010 Oct; 16(19):4742-54. PubMed ID: 20647473
[TBL] [Abstract][Full Text] [Related]
46. Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells.
Sato A; Asano T; Isono M; Ito K; Asano T
BMC Urol; 2014 Aug; 14():71. PubMed ID: 25176354
[TBL] [Abstract][Full Text] [Related]
47. Endoplasmic reticulum stress and autophagy participate in apoptosis induced by bortezomib in cervical cancer cells.
Zhang Y; Bai C; Lu D; Wu X; Gao L; Zhang W
Biotechnol Lett; 2016 Feb; 38(2):357-65. PubMed ID: 26423802
[TBL] [Abstract][Full Text] [Related]
48. Immune checkpoint inhibition improves antimyeloma activity of bortezomib and STING agonist combination in Vk*MYC preclinical model.
Sokolowska O; Rodziewicz-Lurzynska A; Pilch Z; Kedzierska H; Chlebowska-Tuz J; Sosnowska A; Szumera-Cieckiewicz A; Sokol K; Barankiewicz J; Salomon-Perzynski A; Ciepiela O; Lech-Maranda E; Golab J; Nowis D
Clin Exp Med; 2023 Sep; 23(5):1563-1572. PubMed ID: 36044158
[TBL] [Abstract][Full Text] [Related]
49. Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
Tang JH; Yang L; Chen JX; Li QR; Zhu LR; Xu QF; Huang GH; Zhang ZX; Xiang Y; Du L; Zhou Z; Lv SQ
Cancer Commun (Lond); 2019 Dec; 39(1):81. PubMed ID: 31796105
[TBL] [Abstract][Full Text] [Related]
50. Visualizing the antivascular effect of bortezomib on the hypoxic tumor microenvironment.
Sun X; Ackerstaff E; He F; Xing L; Hsiao HT; Koutcher JA; Ling CC; Li GC
Oncotarget; 2015 Oct; 6(33):34732-44. PubMed ID: 26416246
[TBL] [Abstract][Full Text] [Related]
51. Antitumoural immunity by virus-mediated immunogenic apoptosis inhibits metastatic growth of hepatocellular carcinoma.
Boozari B; Mundt B; Woller N; Strüver N; Gürlevik E; Schache P; Kloos A; Knocke S; Manns MP; Wirth TC; Kubicka S; Kühnel F
Gut; 2010 Oct; 59(10):1416-26. PubMed ID: 20675696
[TBL] [Abstract][Full Text] [Related]
52. Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells.
Gu H; Chen X; Gao G; Dong H
Mol Cancer Ther; 2008 Aug; 7(8):2298-307. PubMed ID: 18723477
[TBL] [Abstract][Full Text] [Related]
53. Intercellular transmission of the unfolded protein response promotes survival and drug resistance in cancer cells.
Rodvold JJ; Chiu KT; Hiramatsu N; Nussbacher JK; Galimberti V; Mahadevan NR; Willert K; Lin JH; Zanetti M
Sci Signal; 2017 Jun; 10(482):. PubMed ID: 28588081
[TBL] [Abstract][Full Text] [Related]
54. [Anti-proliferation Effect of NS-398 in Combination with Bortezomib on Multiple Myeloma RPMI 8226 Cells In Vitro].
Que WZ; Chen JM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1426-1430. PubMed ID: 29070119
[TBL] [Abstract][Full Text] [Related]
55. Lercanidipine Synergistically Enhances Bortezomib Cytotoxicity in Cancer Cells via Enhanced Endoplasmic Reticulum Stress and Mitochondrial Ca
Lee AR; Seo MJ; Kim J; Lee DM; Kim IY; Yoon MJ; Hoon H; Choi KS
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817163
[TBL] [Abstract][Full Text] [Related]
56. NEDD4L binds the proteasome and promotes autophagy and bortezomib sensitivity in multiple myeloma.
Huang X; Cao W; Yao S; Chen J; Liu Y; Qu J; Li Y; Han X; He J; Huang H; Zhang E; Cai Z
Cell Death Dis; 2022 Mar; 13(3):197. PubMed ID: 35236820
[TBL] [Abstract][Full Text] [Related]
57.
Zhou H; Lei M; Wang W; Guo M; Wang J; Zhang H; Qiao L; Feng H; Liu Z; Chen L; Hou J; Wang X; Gu C; Zhao B; Izumchenko E; Yang Y; Zhu Y
Aging (Albany NY); 2020 Nov; 12(22):22949-22974. PubMed ID: 33203800
[TBL] [Abstract][Full Text] [Related]
58. Farnesol inhibits tumor growth and enhances the anticancer effects of bortezomib in multiple myeloma xenograft mouse model through the modulation of STAT3 signaling pathway.
Lee JH; Kim C; Kim SH; Sethi G; Ahn KS
Cancer Lett; 2015 May; 360(2):280-93. PubMed ID: 25697480
[TBL] [Abstract][Full Text] [Related]
59. FTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse model.
Szymiczek A; Pastorino S; Larson D; Tanji M; Pellegrini L; Xue J; Li S; Giorgi C; Pinton P; Takinishi Y; Pass HI; Furuya H; Gaudino G; Napolitano A; Carbone M; Yang H
J Transl Med; 2017 Mar; 15(1):58. PubMed ID: 28298211
[TBL] [Abstract][Full Text] [Related]
60. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA
BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
